-
Hypofractionation for Regional Nodal Irradiation in breast cancer: Best of both the worlds Clin. Breast Cancer (IF 3.1) Pub Date : 2024-03-14 Dr Budhi Singh Yadav, Dr Treshita Dey
: Locoregional radiotherapy play an important role in controlling the disease after surgery in patients with breast cancer. Radiotherapy schedules vary from conventional fraction to hypofractionation. The purpose of this review is to get an insight into the data on regional nodal irradiation (RNI) with hypofractionation in patients with breast cancer. : This systematic review was constructed in accordance
-
Combination of DCE-MRI and NME-DWI via Deep Neural Network for Predicting Breast Cancer Molecular Subtypes Clin. Breast Cancer (IF 3.1) Pub Date : 2024-03-13 Zhi-Chang Ba, Hong-Xia Zhang, Ao- Yu Liu, Xin-Xiang Zhou, Lu Liu, Xin-Yi Wang, Abiyasi Nanding, Xi-Qiao Sang, Zi-Xiang Kuai
To explore whether the combination of dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) and non-mono-exponential (NME) model-based diffusion-weighted imaging (DWI) via deep neural network (DNN) can improve the prediction of breast cancer molecular subtypes compared to either imaging technique used alone. This prospective study examined 480 breast cancers in 475 patients undergoing DCE-MRI
-
Nomogram Based on US and Clinicopathologic Characteristics: Axillary Nodal Evaluation Following Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer Clin. Breast Cancer (IF 3.1) Pub Date : 2024-03-13 Jia-Xin Huang, Yi-Jie Chen, Xue-Yan Wang, Jia-Hui Huang, Ke-Hong Gan, Li-Na Tang, Xiao-Qing Pei
To develop a convenient modality to predict axillary response to neoadjuvant chemotherapy (NAC) in breast cancer patients. In this multi-center study, a total of 1019 breast cancer patients with biopsy-proven positive lymph node (LN) receiving NAC were randomly assigned to the training and validation groups at a ratio of 7:3. Clinicopathologic and ultrasound (US) characteristics of both primary tumors
-
Systemic therapy advances for HER2-positive and triple negative breast cancer – what the surgeon needs to know Clin. Breast Cancer (IF 3.1) Pub Date : 2024-03-13 Stephanie Downs-Canner, Anna Weiss
Neoadjuvant systemic therapy (NST) was initially reserved for unresectable patients however it has been increasingly used to facilitate breast conservation, downstage the axilla, and inform adjuvant therapy decisions based on response. For patients with HER2+ and triple negative breast cancer (TNBC), clinical trials have resulted in the ability to individualize treatment regimens.
-
Is immediate breast reconstruction with a latissimus dorsi myocutaneous flap safe for starting adjuvant chemotherapy in patients with breast cancer? Clin. Breast Cancer (IF 3.1) Pub Date : 2024-03-10 Gabriel Salum D'Alessandro, Alexandre Mendonça Munhoz, Fabiana Midori Takeuchi, Alejandro Povedano, João Carlos Sampaio Goes
Immediate breast reconstruction following mastectomy reduces perceptions of mutilation and femininity issues in oncological patients, but surgical complications should not delay chemotherapy. This study evaluated post-surgical complications in patients who underwent radical breast surgery followed by immediate reconstruction with latissimus dorsi myocutaneous flaps and silicone implants, along with
-
The efficiency and toxicity of Anlotinib in combination with Docetaxel followed by Epirubicin and Cyclophosphamide regimen as Neoadjuvant Treatment in IIB to IIIA Triple Negative Breast Cancer: A Single-Arm, Multicenter, Open-Label, Phase II Study Clin. Breast Cancer (IF 3.1) Pub Date : 2024-03-08 Xi Chen, Xinyu Wei, Peizhuo Yao, Yanbin Liu, Haitao Guan, Huafeng Kang, Di Liu, Yan Diao, Xiaobin Ma, Weili Min, Changyou Shan, Yang Zhao, Fang Zhao, Yuanyuan Chen, Dong Xiao, Qing She, Youhuai Liu, Yinbin Zhang, Shuqun Zhang
-
Quality of life outcomes associated with optimization of treatment by omitting radiotherapy in early breast cancer. Clin. Breast Cancer (IF 3.1) Pub Date : 2024-03-06 Lesley Stafford, Michelle Sinclair, Phyllis Butow, Janemary Hughes, Allan Park, Leslie Gilham, Allison Rose, G Bruce Mann
Improved prognosis of early breast cancer (EBC) has created opportunities for treatment optimization but reducing morbidity should not inadvertently compromise quality of life (QoL). PROSPECT used preoperative MRI and pathology findings to identify women suitable for radiotherapy (RT) omission following breast conserving surgery. We retrospectively explored the association between de-escalation by
-
The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC) Clin. Breast Cancer (IF 3.1) Pub Date : 2024-03-06 Elena Michaels, Nan Chen, Rita Nanda
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype, generally associated with a high risk of recurrence and poor prognosis. Our understanding of the heterogeneity of TNBC has increased over the past decade, and with it a recognition that some TNBCs are immunogenically active. This finding has led to the investigation of immunotherapy-based approaches for treatment of both early
-
Expression and clinical significance of NUDCD1, PI3K/AKT/mTOR signaling pathway-related molecules and immune infiltration in breast cancer Clin. Breast Cancer (IF 3.1) Pub Date : 2024-03-06 Wei Wen, Yuehua Li, Xi Cao, Yanyan Li, Ziyi Liu, Zhuoqi Tang, Liming Xie, Rongfang He
NUDCD1 (NudC Domain Containing 1) performs an essential function in biological processes such as cell progression, migration, cell cycle, and intracellular material transport. Many solid tumors express it highly, which is a prospective biomarker and therapeutic approach. However, the expression and clinical importance of NUDCD1 across breast cancer is unclear. The expressions of NUDCD1 in breast cancers
-
Exploring the Oncogenic Potential of TIMM8A: A Crucial Factor in Breast Cancer Tumorigenesis Clin. Breast Cancer (IF 3.1) Pub Date : 2024-03-06 Zhixuan Wu, Adheesh Bhandari, Suzita Hirachan, Rongrong Zhang, Xiaowu Wang, Yuying Zhou
Female breast cancer has become the world's most common malignant tumour, displacing lung malignancy, and the incidence of malignant tumours has increased continuously in recent decades. However, the underlying molecular mechanisms of breast tumorigenesis have not been fully elucidated. By consulting the literature, we discovered that the TIMM8A gene could affect oxidative stress and apoptosis in patients
-
PARP inhibitor for Neoadjuvant therapy in HER2-negative breast cancer: a systematic review and meta-analysis of efficacy and safety Clin. Breast Cancer (IF 3.1) Pub Date : 2024-03-02 Xiaomeng Jia, Kainan Wang, Qiping Zhuo, Zuowei Zhao, Man Li
PARPi is approved for HER2-negative advanced breast cancer with mutation. In recent years, many studies have explored the application of PARPi in neoadjuvant therapy, but failed to reach a unified conclusion. PubMed, Clinicaltrials.gov, Cochrane CENTRAL, Embase and key oncological meetings for trials were searched for studies reporting neoadjuvant regimen with PARPi in HER2-negative breast cancer.
-
SHORT-TERM EFFECTS OF DRY HEAT TREATMENT (FLUIDOTHERAPY) IN THE MANAGEMENT OF BREAST CANCER RELATED LYMPHEDEMA: A RANDOMIZED CONTROLLED STUDY Clin. Breast Cancer (IF 3.1) Pub Date : 2024-03-01 Burcu Duyur Çakıt, Seçil Pervane Vural
To investigate whether fluidotherapy added to complete decongestive therapy (CDT) would provide additional contribution to edema reduction in patients with breast cancer related lymphedema (BCRL). Thirthy-two patients with unilateral BCRL were randomly divided into two groups: standard treatment with CDT only (Group 1) and CDT + fluidotherapy (Group 2). All patients underwent phase 1 CDT, which included
-
Photoacoustic Imaging Radiomics to Identify Breast Cancer in BI-RADS 4 or 5 Lesions Clin. Breast Cancer (IF 3.1) Pub Date : 2024-02-29 Guoqiu Li, Zhibin Huang, Hui Luo, Hongtian Tian, Zhimin Ding, Yaohong Deng, Jinfeng Xu, Huaiyu Wu, Fajin Dong
To develop a nomogram based on photoacoustic imaging (PAI) radiomics and BI-RADs to identify breast cancer (BC) in BI-RADS 4 or 5 lesions detected by ultrasound (US). In this retrospective study, 119 females with 119 breast lesions at US and PAI examination were included (January 2022 to December 2022). Patients were divided into the training set (n = 83) or testing set (n = 36) to develop a nomogram
-
Independent Validation of the BRENDA-Score Breast Cancer Prognosis Prediction Tool In Chinese Patients Clin. Breast Cancer (IF 3.1) Pub Date : 2024-02-28 Shao Ma, Yunxia Liu, Peng Gao, Rong Ma
The BRENDA-Score was developed and used to predict the prognosis of patients with breast cancer (BC). This study was performed to validate the use of this tool in Chinese patients with primary invasive BC patients. Patients underwent surgery for BC from January 2009 to December 2016. Discrimination was assessed by the area under the receiver operating characteristic (ROC) curve (AUC). Calibrations
-
Assessment of Postmastectomy Radiation Therapy Receipt by Age and Association With Outcomes in Women With Breast Cancer Clin. Breast Cancer (IF 3.1) Pub Date : 2024-02-28 Carolina E. Fasola, Elaina Graham, Wei Sha, Courtney R. Schepel, Sally J. Trufan, Anna Hecksher, Richard L. White, Lejla Hadzikadic-Gusic
Postmastectomy radiation therapy (PMRT) reduces locoregional recurrence (LRR) and improves overall survival (OS) in patients with breast cancer. Young age has been recognized as a risk factor for LRR. The primary objective of this study was to determine if recommendations for PMRT differed among patients younger than 50 years as compared to women aged 50 years or older. We reviewed medical records
-
18F-FES PET/CT for Post-Cryoablation Evaluation of Breast Cancer Clin. Breast Cancer (IF 3.1) Pub Date : 2024-02-28 Celina Duran, Robert C. Ward, Elizabeth H. Dibble
-
Clinical Outcomes and Intrinsic Subtypes of Breast Cancer Patients with Single Hormone Receptor-positive Receiving Neoadjuvant Chemotherapy Clin. Breast Cancer (IF 3.1) Pub Date : 2024-02-28 Tingting Wang, Jinnan Wang, Wei Zhao, Yueyin Pan
Extensive studies have highlighted the significance of estrogen receptor (ER) and progesterone receptor (PR) in breast cancer (BRCA). However, our understanding of patients with single hormone receptor (HR)-positive (sHR+) BRCA remains limited. This lack of understanding poses challenges in predicting prognosis and selecting appropriate treatments. We collected data from a total of 825 human epidermal
-
Long-Term Outcomes of S-1 Combined With Low-Dose Docetaxel as Neoadjuvant Chemotherapy (N-1 Study, Phase II Trial) in Patients With Operable Breast Cancer Clin. Breast Cancer (IF 3.1) Pub Date : 2024-02-22 Soichiro Sasa, Hiroaki Inoue, Misako Nakagawa, Hiroaki Toba, Masakazu Goto, Kazumasa Okumura, Mariko Misaki, Tomohiro Inui, Sawaka Yukishige, Aya Nishisho, Naoki Hino, Miyuki Kanematsu, Yoshimi Bando, Hisanori Uehara, Akira Tangoku, Hiromitsu Takizawa
We previously reported that S-1 and low-dose docetaxel (DOC) (N-1 study, phase II trial) could be a well-tolerated and effective neoadjuvant chemotherapies (NACs) for patients with operable breast cancer. Herein, we analyzed the long-term outcomes and developed clinicopathological and molecular predictors of pathological complete response (pCR). Eighty-three patients received S-1 (40 mg/m orally on
-
The Clinicopathological and Prognostic Significance of HER2-Low Breast Cancer: A Comparative Analysis Between HER2-Low and HER2-Zero Subtypes Clin. Breast Cancer (IF 3.1) Pub Date : 2024-02-22 Reiki Nishimura, Yoshitaka Fujiki, Tetsuhiko Taira, Toshiko Miyaki, Shuichi Kanemitsu, Daisuke Yotsumoto, Megumi Teraoka, Junko Kawano, Naomi Gondo, Reiko Mitsueda, Shinichi Baba, Yasuyo Ohi, Yoshiaki Rai, Yoshiaki Sagara, Yasuaki Sagara
HER2-low breast cancer (BC) is a newly defined subset of HER2-negative BC. However, it is still uncertain whether HER2-low BC can be categorized as a distinct biological/clinical subgroup with any prognostic significance. Invasive BC cases (n = 10,215) with Stage I-III were retrospectively analyzed to determine the HER2 status. The HER2 status was then divided into 3 groups: HER2-0, HER2-low, and HER2-positive
-
Through Clinicians' Eyes: Use of an In-consultation Patient Decision Aid in Radiotherapy Treatment for Early Breast Cancer. A Qualitative Study Clin. Breast Cancer (IF 3.1) Pub Date : 2024-02-21 Stine Rauff Søndergaard, Mette Stie, Troels Bechmann, Birgitte Vrou Offersen, Mette Holck Nielsen, Mette Møller, Leonard L. Berry, Robert Zachariae, Karina Dahl Steffensen, Lea Lund
Clinicians’ experience of shared decision making and their use of patient decision aids are crucial for the implementation of shared decision making. Fourteen oncologists and six nurses share their experiences in this paper. Overall, while our findings indicate that the use of an in-consultation patient decision aid (the Decision Helper) requires a change in their practice, the clinicians report that
-
The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial Clin. Breast Cancer (IF 3.1) Pub Date : 2024-02-21 Veronique Debien, Elisa Agostinetto, Marco Bruzzone, Marcello Ceppi, Diogo Martins-Branco, Chiara Molinelli, Flavia Jacobs, Guilherme Nader-Marta, Matteo Lambertini, Evandro de Azambuja
The CLEOPATRA trial (NCT00567190) established a dual anti-HER2 blockade in combination with docetaxel as the first-line standard of care for patients with metastatic HER2-positive breast cancer. While this treatment is overall associated with significant improvement in progression-free survival (PFS) and overall survival (OS), not all patients respond equally. We hypothesized that a radiological complete
-
Stromal Type I Collagen in Breast Cancer: Correlation to Prognostic Biomarkers and Prediction of Chemotherapy Response Clin. Breast Cancer (IF 3.1) Pub Date : 2024-02-21 Malin Jansson, Jessica Lindberg, Gunilla Rask, Johan Svensson, Ola Billing, Anoosheh Nazemroaya, Anette Berglund, Fredrik Wärnberg, Malin Sund
Fibrillar collagens accumulate in the breast cancer stroma and appear as poorly defined spiculated masses in mammography imaging. The prognostic value of tissue type I collagen remains elusive in treatment-naïve and chemotherapy-treated breast cancer patients. Here, type I collagen mRNA and protein expression were analysed in 2 large independent breast cancer cohorts. Levels were related to clinicopathological
-
Biopsy or Follow-up: AI Improves the Clinical Strategy of US BI-RADS 4A Breast Nodules Using a Convolutional Neural Network Clin. Breast Cancer (IF 3.1) Pub Date : 2024-02-20 Mei Yi, Yue Lin, Zehui Lin, Ziting Xu, Lian Li, Ruobing Huang, Weijun Huang, Nannan Wang, Yanling Zuo, Lin Yuan, Dong Ni, Yanyan Zhang, Yingjia Li
To develop predictive nomograms based on clinical and ultrasound features and to improve the clinical strategy for US BI-RADS 4A lesions. Patients with US BI-RADS 4A lesions confirmed as from 3 hospitals between January 2016 and June 2020 were retrospectively included. Clinical and ultrasound features were extracted to establish nomograms CE (based on clinical experience) and DL (based on deep-learning
-
BCAR4 Expression as a Predictive Biomarker for Endocrine Therapy Resistance in Breast Cancer Clin. Breast Cancer (IF 3.1) Pub Date : 2024-02-16 Muheng Liao, Jace Webster, Emily M. Coonrod, Katherine N. Weilbaecher, Christopher A. Maher, Nicole M. White
Breast cancer, particularly the estrogen receptor positive (ER+) subtype, remains a leading cause of cancer-related death among women. Endocrine therapy is the most effective treatment for ER+ breast cancer; however, the development of resistance presents a significant challenge. This study explored the role of the () gene as a potential driver of resistance and a pivotal biomarker in breast cancer
-
A Molecular Typing Method for Invasive Breast Cancer by Serum Raman Spectroscopy Clin. Breast Cancer (IF 3.1) Pub Date : 2024-02-16 Jun Jiang, Lintao Li, Gang Yin, Huaichao Luo, Junjie Li
The incidence of breast cancer ranks highest among cancers and is exceedingly heterogeneous. Immunohistochemical staining is commonly used clinically to identify the molecular subtype for subsequent treatment and prognosis. Raman spectroscopy and support vector machine (SVM) learning algorithm were utilized to identify blood samples from breast cancer patients in order to investigate a novel molecular
-
Impact of Anti-Estrogen Therapy on Early Cardiovascular Referrals, Tests and Medications in Premenopausal Women with Operable Breast Cancer Clin. Breast Cancer (IF 3.1) Pub Date : 2024-02-16 Emily Douglas, Beverly Levine, Ahmer Ansari, Katherine Ansley, Susan Melin, Carolyn J. Park, Karl Richardson, Sarah Hatcher, Ralph B. D'Agostino Jr., Jennifer H. Jordan, Alexandra Thomas
Premenopausal women with high-risk hormone receptor (HR)-positive breast cancer often receive ovarian function suppression (OFS) and anti-estrogen therapy which induces near complete estrogen deprivation (NCED). This treatment improves recurrence-free survival but may increase cardiovascular risk. We sought to identify patterns of cardiovascular care and outcomes in premenopausal women with operable
-
Comparison of PD-L1 (22C3) Expression in Paired Primary and Metastatic Breast Carcinoma Clin. Breast Cancer (IF 3.1) Pub Date : 2024-02-16 Xiao Huang, Sarah A. Anderson, Gene P. Siegal, Shi Wei, Shanrun Liu, Jingyun Yang, Puentes Roisin, J. Taylor Pickens, Lei Huo, Aysegul A. Sahin, Carlos Prieto Granada, Shuojun Chen
PD-L1 immunohistochemistry (IHC) is being used as a predictive marker of the benefit derived from immunotherapy in several cancer types, including breast cancer. However, the insight gleaned of the prognostic and predictive value of PD-L1 status and its correlation with molecular characteristics during breast cancer progression remains limited. We performed an PD-L1 (22C3) assay in pre-treatment primary
-
Avoiding Locoregional Overtreatment in Older Adults With Early-Stage Breast Cancer Clin. Breast Cancer (IF 3.1) Pub Date : 2024-02-13 Eliza H. Lorentzen, Christina A. Minami
Advances in the treatment of older women with early-stage breast cancer, particularly opportunities for de-escalation of therapy, have afforded patients and providers opportunity to individualize care. As the majority of women ≥65 have estrogen receptor-positive, HER2-negative disease, locoregional therapy (surgery and/or radiation) may be tailored based on a patient's physiologic age to avoid either
-
The Role of Magnetic Resonance Imaging in the Preoperative Staging and Treatment of Invasive Lobular Carcinoma Clin. Breast Cancer (IF 3.1) Pub Date : 2024-02-07 Laura P.A. Willen, Merel A. Spiekerman van Weezelenburg, Aike A. Bruijsten, Pieter P.H.L. Broos, Elisabeth R.M. van Haaren, Alfred Janssen, Yvonne L.J. Vissers, James van Bastelaar
Invasive lobular carcinoma (ILC) is known for its diffuse growth pattern and its associated challenges in diagnosing. Magnetic resonance imaging (MRI) is the most accurate imaging modality and might aid in improving preoperative staging compared to full field digital mammography (FFDM) and ultrasound (US), however current literature is inconsistent. The aim of this paper is to evaluate the accuracy
-
Construction and validation of a nomogram predicting the overall survival benefit of unilateral breast cancer patients undergoing contralateral prophylactic mastectomy Clin. Breast Cancer (IF 3.1) Pub Date : 2024-02-07 Luyao Dai, Wenyu Yan, Xueting Ren, Dandan Liu, Lidan Chang, Shuai Lin, Hao Wu, Huafeng Kang, Xiaobin Ma
Currently, research on the prognostic factors of unilateral breast cancer (UBC) patients receiving contralateral prophylactic mastectomy (CPM) is limited. This study aimed to construct a new nomogram to predict these patients' overall survival (OS). In this retrospective study, 88477 patients who underwent CPM or unilateral mastectomy (UM) were selected from the Surveillance, Epidemiology, and End
-
Re: ‘Diagnostic delays in breast cancer among young women: An Emphasis on healthcare providers’ by Costa et al. Clin. Breast Cancer (IF 3.1) Pub Date : 2024-02-06 Omobolade Sonola
-
-
Feasibility of Omitting Sentinel Lymph Node Biopsy in an Under-screened Cohort of Breast Cancer Patients With a Premastectomy Diagnosis of Ductal Carcinoma In Situ Clin. Breast Cancer (IF 3.1) Pub Date : 2024-02-05 Jinnie Pang, Zhiyan Yan, Qing Ting Tan, John C. Allen, Mingjia Wang, Geok Hoon Lim
Nodal involvement in ductal carcinoma in situ (DCIS) is rare. In patients with DCIS diagnosis prior to mastectomy, a sentinel lymph node biopsy (SLNB) is usually performed during mastectomy, to avoid the risk of reoperation and the non-identification of SLN subsequently, should there be an upgrade to invasive cancer. We aimed to study the feasibility of omitting SLNB in an under-screened cohort, with
-
-
A Comprehensive Assessment of Radial Scars on Core Needle Biopsy in Patients with or without Breast Cancer: Upgrade Rate and Implications on Management Clin. Breast Cancer (IF 3.1) Pub Date : 2024-02-02 Arith Reyes, Luona Sun, Richard Ha, Elise Desperito, Marc Brown, Mark A. Francescone, Stacy Ugras, Lisa Wiechmann, Roshni Rao, Bret Taback
Radial scars/radial sclerosing lesions (RS) are benign breast lesions identified on core needle biopsy (CNB) which can upgrade to malignancy at excision. There is limited data on RS detection and upgrade rates with more sensitive imaging such as magnetic resonance imaging (MRI) and none during their detection for breast cancer workup and its implication on patient treatment decisions. A retrospective
-
Correlation between Quantitative Parameters Obtained by Dual Energy Spectral CT and Prognostic Histopathological Factors and Biomarkers in Breast Cancer Clin. Breast Cancer (IF 3.1) Pub Date : 2024-02-02 Nurgül Orhan Metin, Sinan Balcı, Yavuz Metin, Filiz Taşçı, Melih Gaffar Gözükara
This study was performed to investigate the correlation between parameters of dual energy spectral computed tomography (DESCT) and various histopathological factors and, biomarkers associated with the prognosis of breast cancer. The relevant data were obtained from 116 female breast cancer patients. ER- and PR-negative tumors had significantly higher values of IE and nIE. HER2 overexpressed and Ki-67
-
Omission of Breast Surgery in Exceptional Responders Clin. Breast Cancer (IF 3.1) Pub Date : 2024-02-01 Marios-Konstantinos Tasoulis, Han-Byoel Lee, Henry Mark Kuerer
Breast cancer management has transformed significantly over the last decades, primarily through the integration of neoadjuvant systemic therapy (NST) and the evolving understanding of tumor biology, enabling more tailored treatment strategies. The aim of this review is to critically present the historical context and contemporary evidence surrounding the potential of omission of surgery post-NST, focusing
-
Prognosis and adjusting factors in elderly patients with triple-negative breast cancer: comparing with young and middle age groups Clin. Breast Cancer (IF 3.1) Pub Date : 2024-01-30 Yong Ho You, Min Kyoon Kim, Joo Yun Lee
Purpose Proper breast cancer screening and treatment should be considered in the elderly population; however, some tend to be less proactive. Our study aimed to investigate the impact of old age on treatment and prognosis in triple-negative breast cancer (TNBC). Method The study included patients with primary TNBC stage I-III diagnosed from 2002 to 2019 in single institution and retrospectively analysed
-
Elucidating Axillary Soft Tissue Involvement in Breast Cancer: Unveiling Metastatic Mechanisms and Therapeutic Perspectives Clin. Breast Cancer (IF 3.1) Pub Date : 2024-01-29 Kefah Mokbel
This perspective focuses on axillary soft tissue (AXT) involvement in breast cancer, revealing diverse pathological entities beyond traditional axillary lymph node metastasis. AXT involvement is linked to increased risks of distant metastasis and locoregional failure, emphasizing its significance in predicting breast cancer outcomes. We posit that AXT involvement could signify a retrograde metastatic
-
Can we do breast-conserving surgery without intraoperative frozen section of margin? Clin. Breast Cancer (IF 3.1) Pub Date : 2024-01-29 Dongyan Xu, Kaiyue Wang, Chen Lin, Dan Li, Chi Pan, Kaimin Hu, Huihui Chen, Fengbo Huang, Wei Tian, Yiding Chen, Tao Pan
Purpose This study was a retrospective and non-randomized study to assess the safety and reliability of identifying the surgical margin in breast cancer breast-conserving surgery (BCS) by using intraoperative ultrasonic location and specimen mammography instead of traditional intraoperative frozen pathological section. Methods Among the patients who underwent BCS from May 2019 to October 2021, according
-
The impact of miRNAs on the efficacy of Tamoxifen in breast cancer treatment.: A systematic review Clin. Breast Cancer (IF 3.1) Pub Date : 2024-01-26 Nima Nikbin Kavishahi, Aryan Rezaee, Sara Jalalian
Introduction : 70% of breast cancer patients have an active estrogen receptor. Tamoxifen illustrates this therapy, interfering with estrogen's ability to bind to cancer cells. The most challenging aspect of Tamoxifen, however, is that breast cancer cells become resistant to its effects. Some studies have shown that alterations in miRNA expression contribute significantly to drug resistance in breast
-
Inhibitory impact of cinobufagin in triple-negative breast cancer metastasis: involvements of macrophage reprogramming through upregulated MME and inactivated FAK/STAT3 signaling Clin. Breast Cancer (IF 3.1) Pub Date : 2024-01-26 Zhaohui Zhu, Hanlu Wang, Xu Qian, Meiling Xue, Aijun Sun, Yifei Yin, Jinhai Tang, Jian Zhang
-
Effect of T stages on the choice of axillary evaluation modality in breast cancer patients with 1-2 sentinel lymph node metastases Clin. Breast Cancer (IF 3.1) Pub Date : 2024-01-24 Dandan Liu, Lidan Chang, Xuyan Zhao, Luyao Dai, Hanxiao Cui, Peinan Liu, Zhen Zhai, Hao Wu, Xiaobin Ma, Huafeng Kang
Introduction The survival benefit of axillary lymph node dissection (ALND), sentinel lymph node biopsy (SLNB) combined with radiation, and ALND combined with radiation remains unclear in breast cancer (BC) patients with 1-2 metastatic sentinel lymph nodes (SLNs). This study aims to rigorously evaluate the prognostic impact of these axillary evaluation modalities on BC patients with varying T-stages
-
Nipple reconstruction using the “arrow flap” technique: outcomes and patients satisfaction Clin. Breast Cancer (IF 3.1) Pub Date : 2024-01-24 Vito Cazzato, Chiara Stocco, Alessandro Scian, Luigi Bonat Guarini, Giulia Benedetta Sidoti, Nadia Renzi, Vittorio Ramella, Giovanni Papa
Introduction Skin-sparing mastectomy (SSM) entails complete removal of the breast tissue and the nipple and areola complex (NAC) with preservation of as much of the overlying skin as possible. The preservation of the natural skin envelope during SSM improves the aesthetic outcome of immediate breast reconstruction, but the lack of NAC determines that the reconstructed breast remains anatomically incomplete
-
ANTIBODY-DRUG CONJUGATES IN TRIPLE NEGATIVE BREAST CANCER Clin. Breast Cancer (IF 3.1) Pub Date : 2024-01-20 Merve Keskinkilic, Ruth Sacks
Triple negative breast cancer (TNBC) accounts for 15-20% of all breast cancer. It is a heterogeneous breast cancer subtype with a poor prognosis. Given these negative features, there is a need for new treatment options beyond conventional chemotherapy in both the early stage and palliative setting. Impressive results have been reported with antibody drug conjugates (ADCs) that link a cytotoxic payload
-
A retrospective audit of the triage process introduced for breast referrals received during the Covid-19 pandemic. Clin. Breast Cancer (IF 3.1) Pub Date : 2024-01-20 E. Mackender, R. Dave, D. Tudor, JR Harvey
Purpose Due to restrictions on breast clinic appointments during the COVID-19 pandemic, a triage process was introduced for new patient referrals. The robustness of this process was examined by analysing the incidence of cancer diagnosis and wait times to treatment. Methods Patients were triaged by secondary care consultant surgeons to an urgent appointment if they had high-risk symptoms based on pre-specified
-
New Strategies for Locally Advanced Breast Cancer: A Review of Inflammatory Breast Cancer and Nonresponders Clin. Breast Cancer (IF 3.1) Pub Date : 2024-01-21 Simran Malhotra, Audree B. Tadros
This review explores the new strategies around the management of locally advanced breast cancer (LABC), particularly for nonresponsive tumors and/or initially unresectable tumors at diagnosis, inclusive of inflammatory breast cancer. Nonresponders to neoadjuvant systemic therapy present a unique clinical challenge. Emerging medical therapeutics as well as considerations for use of radiotherapy and/or
-
Assessment of Oxygen Saturation in Breast Lesions Using Photoacoustic Imaging: Correlation with Benign and Malignant Disease Clin. Breast Cancer (IF 3.1) Pub Date : 2024-01-17 Zhibin Huang, Hongtian Tian, Hui Luo, Keen Yang, Jing Chen, Guoqiu Li, Zhimin Ding, Yuwei Luo, Shuzhen Tang, Jinfeng Xu, Huaiyu Wu, Fajin Dong
Background Hypoxia is a hallmark of breast cancer (BC). Photoacoustic (PA) imaging, based on the use of laser-generated ultrasound (US), can detect oxygen saturation (So2) in the tissues of breast lesion patients. Purpose To measure the oxygenation status of tissue in and on both sides of the lesion in breast lesion participants using a multimodal Photoacoustic/ultrasound (PA/US) imaging system and
-
Prediction of Disease-free Survival in Breast Cancer using Deep Learning with Ultrasound and Mammography: A multicenter study Clin. Breast Cancer (IF 3.1) Pub Date : 2024-01-17 Junqi Han, Hui Hua, Jie Fei, Jingjing Liu, Yijun Guo, Wenjuan Ma, Jingjing Chen
Background Breast cancer is a leading cause of cancer morbility and mortality in women. The possibility of overtreatment or inappropriate treatment exists, and methods for evaluating prognosis need to be improved. Materials and Methods Patients (from January 2013 to December 2018) were recruited and divided into a training group and a testing group. All patients were followed for more than 3 years
-
Advocating for Enhanced Patient Engagement in Breast Cancer Care: Impact of Residual Increased Lateral Adiposity and Consideration of the Pursuit of ‘Living Flat’ Clin. Breast Cancer (IF 3.1) Pub Date : 2024-01-17 Aaron J Knowles
Introduction Breast cancer is a significant health concern, accounting for a substantial proportion of cancer cases. Despite improvements in cancer survivorship, many women still require mastectomy as part of their therapeutic treatment. Mastectomy alone or delayed breast reconstruction (DBR) are two options available to women not suitable for immediate breast reconstruction at initial mastectomy.
-
Cyclin-dependent kinase 4/6 inhibitors as neoadjuvant therapy of hormone receptor-positive/HER2-negative early breast cancer: What do we know so far? Clin. Breast Cancer (IF 3.1) Pub Date : 2024-01-16 Ioanna Ploumaki, Efthymios Triantafyllou, Ioannis-Alexios Koumprentziotis, Konstantinos Karampinos, Konstantinos Drougkas, Ioannis Karavolias, Elias Kotteas
The introduction of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors to the treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer is regarded as one of the greatest achievements of the last decades in breast oncology. To date, palbociclib, abemaciclib and ribociclib are the three approved CDK4/6 inhibitors that combined with
-
Alpelisib-induced diabetic ketoacidosis: a pharmacovigilance analysis of the FDA Adverse Event Reporting System and review of the literature Clin. Breast Cancer (IF 3.1) Pub Date : 2024-01-14 Julia L. Ziegengeist, Joseph B. Elmes, Scott A. Strassels, Jai N. Patel, Donald C. Moore
Background Alpelisib is a PI3K inhibitor indicated with fulvestrant for treatment of advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated breast cancer. In the phase III SOLAR-1 trial, grade 3/4 hyperglycemic events were reported in 36.6% of patients receiving alpelisib-fulvestrant compared to 0.7% receiving placebo-fulvestrant
-
The importance of naming structural racism as a root cause of racial inequities in breast cancer outcomes. Clin. Breast Cancer (IF 3.1) Pub Date : 2024-01-14 Francois G. Rollin, Spencer Lee-Rey, Elaina Wong-Serrano, Sydney Habert, Mehul Tejani
Abstract not available
-
Effects of Neoadjuvant Chemotherapy on Autologous and Implant-Based Breast Reconstruction: A Systematic Review and Meta-Analysis of the Literature Clin. Breast Cancer (IF 3.1) Pub Date : 2024-01-10 Shayoni Nag, Levana Berlin, Krystal Hunter, Steven C. Bonawitz
Background Neoadjuvant chemotherapy (NAC) is a standard modality of treatment for breast cancer.1 The exposure of patients to drugs that effect the cells and processes involved in healing prior to reconstructive surgical procedures is a source of concern for reconstructive surgeons. The reported effects of NAC on autologous and tissue expander to implant-based breast reconstruction vary from study
-
Emerging Role of Robotic Surgery in the Breast Clin. Breast Cancer (IF 3.1) Pub Date : 2024-01-09 Alissa Doll, Katherine Kopkash, Jennifer Baker
In recent years, there has been increased adoption of robotic technology in oncologic breast surgery, particularly with the use of robotic nipple sparing mastectomy (r-NSM). Here we review the emergence of robotic-assisted surgery in breast procedures, and discuss the safety, limited oncologic outcomes, apparent advantages, and potential limitations of r-NSM compared to conventional open-NSM (c-NSM)
-
Implications of Highly Penetrant Genetic Variants on Breast Surgery Clin. Breast Cancer (IF 3.1) Pub Date : 2024-01-07 Matthew G. Davey, Shona Tormey
It seems the most probable beneficiaries from the molecular era are those harboring hereditary genetic variants, which are responsible for 5-10% of all breast cancer diagnoses. There are several key implications of such variants on clinical practice, from expedited anticipation of primary cancer diagnoses, which can have their risk mitigated by risk reduction surgery, to pragmatism surrounding the
-
-
-
Adjuvant Hypofractionated Whole Breast Irradiation (WBI) Versus Accelerated Partial Breast Irradiation (APBI) in Postmenopausal Women with Early Stage Breast Cancer: 5-Years Update of the HYPAB Trial. Clin. Breast Cancer (IF 3.1) Pub Date : 2024-01-05 L. Lo Faro, A. Fogliata, D. Franceschini, R. Spoto, L. Dominici, A. Bertolini, S. Stefanini, V. Vernier, M.B. Ilieva, M Scorsetti
Therapeutical strategies in breast cancer are continuously updating. Recent researches assessed the possibility of irradiating only the surgical bed in selected patients (Partial Breast Irradiation, PBI). In 2014 we designed a study to evaluate toxicity and cosmesis of APBI using Volumetric Modulated Arc Therapy-Rapid Arc compared with hypofractionated whole breast irradiation (WBI). We present here
-
Prognostic value and distribution pattern of tumor infiltrating lymphocytes and their subsets in distant metastases of advanced breast cancer Clin. Breast Cancer (IF 3.1) Pub Date : 2023-12-30 Xin-yi Sun, Cheng-qin Wang, Yan Mao, Zhen-qi Zhang, Jian Cui, Xian-ning Dong, Hai-bo Wang
Background There are significant correlations between the levels of tumor infiltrating lymphocytes (TILs) and the prognosis of primary breast cancer. While little is known about immunological mechanisms in the distant metastasis of advanced breast cancer. Patients and Methods A total of 106 patients with advanced metastatic breast cancer were enrolled in this study between 2016 and 2022.H&E staining